Welcome to our dedicated page for Kenvue SEC filings (Ticker: KVUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kenvue Inc. (NYSE: KVUE) SEC filings, giving investors a primary source for the company’s regulatory disclosures. As the world’s largest pure-play consumer health company by revenue, Kenvue uses its SEC reports to detail financial performance, risk factors, governance matters and significant corporate events related to its portfolio of brands such as Aveeno®, BAND-AID® Brand, Johnson’s®, Listerine®, Neutrogena®, Tylenol® and Zyrtec®.
Among the most important documents for KVUE are current reports on Form 8-K. In 2025, Kenvue filed several 8-Ks to furnish quarterly earnings press releases and to describe leadership changes, preliminary financial results and the Board’s comprehensive review of strategic alternatives. A key 8-K filed on November 3, 2025 outlines an Agreement and Plan of Merger with Kimberly-Clark Corporation, under which a Kimberly-Clark subsidiary will merge with and into Kenvue and Kenvue will ultimately become part of a wholly owned Kimberly-Clark subsidiary. That filing explains the merger structure, the cash and stock consideration for each share of Kenvue common stock, conditions to closing, and termination and fee provisions.
Investors can also use Kenvue’s filings to understand how management presents non-GAAP financial measures. The company’s 8-K earnings materials define metrics such as Adjusted gross profit margin, Adjusted operating income and margin, Adjusted net income, Adjusted diluted earnings per share, Adjusted EBITDA margin, Adjusted effective tax rate, Free cash flow and Organic sales, and reconcile them to the most comparable U.S. GAAP measures. These disclosures clarify how Kenvue evaluates operating efficiency, profitability and cash generation over time.
On this page, Stock Titan surfaces Kenvue’s SEC submissions as they are made available on EDGAR and pairs them with AI-powered summaries to explain the key points in plain language. Users can quickly scan new 10-K and 10-Q reports when filed, review 8-Ks for material events such as the Kimberly-Clark merger agreement or leadership transitions, and examine any proxy materials related to shareholder votes. This combination of real-time filings access and AI explanations helps investors follow how regulatory disclosures may affect KVUE shareholders and the future of the Kenvue business within the consumer health sector.
Kenvue Inc. reported that Chief People Officer Luani Alvarado acquired 79,407 Restricted Stock Units as a grant. Each unit corresponds 1-for-1 with Kenvue common stock and was awarded at no cash cost. The award vests in three equal installments on 03/02/2027, 03/02/2028, and 03/02/2029, contingent on continued service through each vesting date. Following this grant, Alvarado directly holds 79,407 restricted stock units.
Kenvue Inc. reported that Group President North America Carlos De Jesus acquired 127,051 restricted stock units (RSUs) on March 2, 2026 as an equity award. Each RSU corresponds one-for-one with Kenvue common stock. The award vests in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029, contingent on his continued service with the company.
Perry Kirk reported acquisition or exercise transactions in this Form 4 filing.
Kenvue Inc. reported that Chief Executive Officer Perry Kirk received a grant of 491,662 restricted stock units that correspond one-for-one with Kenvue common stock. The award was granted on 03/02/2026 and will vest in three equal installments on 03/02/2027, 03/02/2028, and 03/02/2029, subject to his continued service with the company.
Kenvue Inc. reported that Chief Scientific Officer Caroline Tillett acquired 63,525 Restricted Stock Units as an equity award. The units were granted at no cash cost and correspond one-for-one with Kenvue common stock.
This award vests in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029, as long as Tillett continues to serve at the company through each vesting date. All 63,525 RSUs are currently reported as directly owned following the grant.
Stevens Meredith reported acquisition or exercise transactions in this Form 4 filing.
Kenvue Inc. Chief Operations Officer Meredith Stevens received a grant of 92,641 restricted stock units that correspond 1-for-1 with Kenvue common stock. The award was granted as of 03/02/2026 and will vest in three equal installments on 03/02/2027, 03/02/2028, and 03/02/2029, subject to her continued service.
Kenvue Inc. reported that Chief Digital & Marketing Officer Jonathan Halvorson acquired 51,879 restricted stock units as a compensation award. The units were granted at no cash cost and correspond one-for-one with Kenvue common stock. The award vests in three equal installments on 03/02/2027, 03/02/2028, and 03/02/2029, conditioned on his continued service with the company.
Kenvue Inc. reported that Chief Corp. Affairs Officer Russell Dyer acquired a grant of 43,673 restricted stock units (RSUs), each corresponding 1-for-1 with Kenvue common stock. The award vests in three equal installments on March 2, 2027, March 2, 2028, and March 2, 2029, contingent on his continued service through each vesting date.
Kenvue Inc. files its annual report describing a global consumer health business built on iconic brands and a major pending merger.
The company reports $15.1 billion in Net sales in fiscal 2025, positioning it as the world’s largest pure-play consumer health company by revenue. It operates three segments—Self Care, Skin Health and Beauty, and Essential Health—across more than 165 countries, supported by a sizable in-house and third‑party manufacturing and distribution network.
The filing details Kenvue’s post‑separation evolution from Johnson & Johnson, its extensive regulatory environment, sustainability and human‑capital strategies, and a proposed combination with Kimberly‑Clark. Shareholders of both firms have approved the merger, which still requires additional foreign regulatory clearances and other customary conditions.
Kenvue Inc. Chief Operations Officer Meredith Stevens reported multiple equity transactions tied to previously granted Restricted Stock Units (RSUs). On this date, RSUs for 24,825 units and 3,215 units were exercised and converted into common stock at a stated price of $0.00 per share, reflecting vesting of equity awards rather than open-market purchases. Related common stock entries show matching acquisitions of 24,825 shares and 3,215 shares, increasing her direct holdings.
To cover tax obligations upon RSU vesting, 7,147 shares and 884 shares of common stock were disposed of at $18.66 per share, consistent with tax-withholding transactions rather than discretionary sales. Following these movements, Stevens directly owned 86,046.18 shares of Kenvue common stock. Footnotes state that some awards are now fully vested and that the RSUs were originally granted by Johnson & Johnson and converted into Kenvue RSUs in connection with Kenvue’s separation, with adjustments to preserve award value and performance treated as achieved under specified conditions.
Kenvue Inc. Chief People Officer Luani Alvarado reported multiple equity transactions involving Restricted Stock Units (RSUs) and common stock on February 13, 2026. RSUs covering 14,120 and 1,822 shares were exercised or converted into common stock at a stated price of $0.00 per share.
To cover tax obligations upon RSU vesting, Alvarado disposed of 4,843 and 625 common shares at $18.66 per share through tax-withholding transactions, not open-market sales. Following these transactions, Alvarado directly owned 57,076.14 Kenvue common shares.
Footnotes explain that the RSUs were originally granted by Johnson & Johnson and were converted into Kenvue time-based RSUs in connection with Kenvue’s separation, with this award now fully vested.